Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals Announces Preliminary 2023 Financial Results and Updates
Summary
Alnylam Pharmaceuticals, Inc. announced its preliminary fourth quarter and full year 2023 global net product revenues, highlighting strong growth across its product portfolio. The company reported approximately $346 million in net product revenues for Q4 2023 and $1.241 billion for the full year, with a 39% annual growth. Alnylam also maintained a robust balance sheet with cash, cash equivalents, and marketable securities totaling approximately $2.4 billion at year-end 2023. The company attributed the growth to increased demand for its RNAi therapeutics and positive clinical results from its pipeline programs. Management will discuss these results further during a webcast presentation at the 42nd Annual J.P. Morgan Healthcare Conference.
Profitelligence Alerts
Get alerts for ALNY
Be first to know when Alnylam Pharmaceuticals Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals Inc. is a pioneering biotechnology company dedicated to transforming the lives of patients through RNA interference (RNAi) therapeutics. This scientific approach allows for innovative treatments that can silence genes responsible for certain diseases, offering a unique angle on genetic therapies. Alnylam's primary focus is on developing therapeutics for genetic, cardio-metabolic, hepatic infectious, and central nervous system diseases, contributing to redefining how these conditions are treated. The company's groundbreaking work in RNAi provides a platform for addressing otherwise untreatable or poorly managed medical conditions, positioning it as a leader in the biotechnology sector. With numerous collaborations, partnerships, and a growing pipeline of therapeutics, Alnylam plays a crucial role in advancing modern medicine and contributing to the evolving landscape of genetic therapeutics. Headquartered in Cambridge, Massachusetts, Alnylam underscores the critical intersection of innovation, medicine, and gene science in the financial and pharmaceutical markets.
Official SEC Documents
Advertisement